309 related articles for article (PubMed ID: 35741318)
1. Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.
Takahara T; Satou A; Tsuzuki T; Nakamura S
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741318
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
3. An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.
Satou A; Takahara T; Nakamura S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681627
[TBL] [Abstract][Full Text] [Related]
4. [Pathological diagnosis of Hodgkin lymphoma].
Tamaru J
Nihon Rinsho; 2014 Mar; 72(3):450-5. PubMed ID: 24724402
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
6. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
9. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.
Piris MA; Medeiros LJ; Chang KC
Pathology; 2020 Jan; 52(1):154-165. PubMed ID: 31699300
[TBL] [Abstract][Full Text] [Related]
12. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
14. A 2020 Vision Into Hodgkin Lymphoma Biology.
Hurwitz SN; Bagg A
Adv Anat Pathol; 2020 Sep; 27(5):269-277. PubMed ID: 32482966
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Skinnider BF; Elia AJ; Gascoyne RD; Trümper LH; von Bonin F; Kapp U; Patterson B; Snow BE; Mak TW
Blood; 2001 Jan; 97(1):250-5. PubMed ID: 11133768
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition in Hodgkin Lymphoma.
Moy RH; Younes A
Hemasphere; 2018; 2(1):e20. PubMed ID: 31723749
[TBL] [Abstract][Full Text] [Related]
17. Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.
Carreau NA; Diefenbach CS
Ther Adv Hematol; 2019; 10():2040620719846451. PubMed ID: 31105921
[TBL] [Abstract][Full Text] [Related]
18. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
20. The Grey Zones of Classic Hodgkin Lymphoma.
Bosch-Schips J; Granai M; Quintanilla-Martinez L; Fend F
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
